nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Doxorubicin—kidney cancer	0.592	1	CbGbCtD
Lubiprostone—CLCN2—Stimuli-sensing channels—RYR1—kidney cancer	0.0122	0.16	CbGpPWpGaD
Lubiprostone—CLCN2—gonad—kidney cancer	0.00872	0.278	CbGeAlD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—kidney cancer	0.00796	0.105	CbGpPWpGaD
Lubiprostone—CLCN2—Ion channel transport—RYR1—kidney cancer	0.00795	0.104	CbGpPWpGaD
Lubiprostone—CLCN2—Ion channel transport—ATP7B—kidney cancer	0.00456	0.06	CbGpPWpGaD
Lubiprostone—CBR1—nephron tubule—kidney cancer	0.00429	0.137	CbGeAlD
Lubiprostone—CBR1—Vincristine—Vinblastine—kidney cancer	0.00409	0.68	CbGdCrCtD
Lubiprostone—CBR1—renal system—kidney cancer	0.0039	0.124	CbGeAlD
Lubiprostone—CBR1—kidney—kidney cancer	0.00377	0.12	CbGeAlD
Lubiprostone—CBR1—cortex of kidney—kidney cancer	0.00367	0.117	CbGeAlD
Lubiprostone—CBR1—gonad—kidney cancer	0.0035	0.112	CbGeAlD
Lubiprostone—CBR1—cardiac atrium—kidney cancer	0.00349	0.111	CbGeAlD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—kidney cancer	0.00305	0.0401	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—PTGS1—kidney cancer	0.00287	0.0378	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—RYR1—kidney cancer	0.00277	0.0364	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—SLC5A3—kidney cancer	0.00212	0.0279	CbGpPWpGaD
Lubiprostone—CBR1—Azacitidine—Gemcitabine—kidney cancer	0.00193	0.32	CbGdCrCtD
Lubiprostone—CBR1—NRF2 pathway—KEAP1—kidney cancer	0.00186	0.0244	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.00185	0.0244	CbGpPWpGaD
Lubiprostone—CLCN2—Stimuli-sensing channels—RAF1—kidney cancer	0.00159	0.0209	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.00159	0.0209	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.00159	0.0209	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.00159	0.0209	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—SLC5A5—kidney cancer	0.00112	0.0147	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—PTGS2—kidney cancer	0.0011	0.0145	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—SLC2A1—kidney cancer	0.00108	0.0142	CbGpPWpGaD
Lubiprostone—CLCN2—Ion channel transport—RAF1—kidney cancer	0.00104	0.0137	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—EGR1—kidney cancer	0.001	0.0132	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000944	0.0124	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTP1—kidney cancer	0.000902	0.0119	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000838	0.011	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTM1—kidney cancer	0.000829	0.0109	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000809	0.0106	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000639	0.0084	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ACY1—kidney cancer	0.000606	0.00797	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000517	0.0068	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PDHB—kidney cancer	0.000516	0.00678	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CCBL1—kidney cancer	0.000485	0.00637	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.000438	0.00576	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GLIPR1—kidney cancer	0.00042	0.00553	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PPAT—kidney cancer	0.00042	0.00553	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	0.000415	0.00546	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.000411	0.0054	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—APRT—kidney cancer	0.000391	0.00514	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—FH—kidney cancer	0.000391	0.00514	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.000382	0.00502	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GPC3—kidney cancer	0.000367	0.00483	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—RAF1—kidney cancer	0.000361	0.00475	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CA2—kidney cancer	0.000357	0.0047	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ALAD—kidney cancer	0.000348	0.00458	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ST3GAL2—kidney cancer	0.00034	0.00447	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ALDH1A1—kidney cancer	0.000332	0.00437	CbGpPWpGaD
Lubiprostone—Urinary tract infection—Capecitabine—kidney cancer	0.000321	0.00109	CcSEcCtD
Lubiprostone—Chest pain—Gemcitabine—kidney cancer	0.00032	0.00109	CcSEcCtD
Lubiprostone—Myalgia—Gemcitabine—kidney cancer	0.00032	0.00109	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PGK1—kidney cancer	0.000319	0.00419	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SLC5A3—kidney cancer	0.000319	0.00419	CbGpPWpGaD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000317	0.00108	CcSEcCtD
Lubiprostone—Nervous system disorder—Vincristine—kidney cancer	0.000317	0.00108	CcSEcCtD
Lubiprostone—Asthenia—Erlotinib—kidney cancer	0.000316	0.00108	CcSEcCtD
Lubiprostone—Mental disorder—Paclitaxel—kidney cancer	0.000316	0.00108	CcSEcCtD
Lubiprostone—Discomfort—Gemcitabine—kidney cancer	0.000316	0.00107	CcSEcCtD
Lubiprostone—Malnutrition—Paclitaxel—kidney cancer	0.000314	0.00107	CcSEcCtD
Lubiprostone—Erythema—Paclitaxel—kidney cancer	0.000314	0.00107	CcSEcCtD
Lubiprostone—Decreased appetite—Dactinomycin—kidney cancer	0.000314	0.00107	CcSEcCtD
Lubiprostone—Diarrhoea—Vinblastine—kidney cancer	0.000314	0.00107	CcSEcCtD
Lubiprostone—Abdominal pain—Sorafenib—kidney cancer	0.000314	0.00107	CcSEcCtD
Lubiprostone—Diarrhoea—Everolimus—kidney cancer	0.000313	0.00106	CcSEcCtD
Lubiprostone—CBR1—Metabolism—LDHB—kidney cancer	0.000312	0.00411	CbGpPWpGaD
Lubiprostone—Gastrointestinal pain—Sunitinib—kidney cancer	0.000312	0.00106	CcSEcCtD
Lubiprostone—Hyperhidrosis—Vincristine—kidney cancer	0.000312	0.00106	CcSEcCtD
Lubiprostone—Fatigue—Dactinomycin—kidney cancer	0.000312	0.00106	CcSEcCtD
Lubiprostone—Flatulence—Paclitaxel—kidney cancer	0.00031	0.00105	CcSEcCtD
Lubiprostone—Pain—Dactinomycin—kidney cancer	0.000309	0.00105	CcSEcCtD
Lubiprostone—Anorexia—Vincristine—kidney cancer	0.000308	0.00105	CcSEcCtD
Lubiprostone—Dysgeusia—Paclitaxel—kidney cancer	0.000308	0.00105	CcSEcCtD
Lubiprostone—Oedema—Gemcitabine—kidney cancer	0.000306	0.00104	CcSEcCtD
Lubiprostone—Dizziness—Vinblastine—kidney cancer	0.000303	0.00103	CcSEcCtD
Lubiprostone—Dizziness—Everolimus—kidney cancer	0.000302	0.00103	CcSEcCtD
Lubiprostone—Muscle spasms—Paclitaxel—kidney cancer	0.000302	0.00103	CcSEcCtD
Lubiprostone—Abdominal pain—Sunitinib—kidney cancer	0.000302	0.00103	CcSEcCtD
Lubiprostone—Diarrhoea—Erlotinib—kidney cancer	0.000302	0.00103	CcSEcCtD
Lubiprostone—Nervous system disorder—Gemcitabine—kidney cancer	0.0003	0.00102	CcSEcCtD
Lubiprostone—Feeling abnormal—Dactinomycin—kidney cancer	0.000298	0.00101	CcSEcCtD
Lubiprostone—Skin disorder—Gemcitabine—kidney cancer	0.000298	0.00101	CcSEcCtD
Lubiprostone—Hyperhidrosis—Gemcitabine—kidney cancer	0.000296	0.00101	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000296	0.00101	CcSEcCtD
Lubiprostone—Tremor—Paclitaxel—kidney cancer	0.000294	0.001	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000294	0.001	CcSEcCtD
Lubiprostone—Hypersensitivity—Sorafenib—kidney cancer	0.000292	0.000994	CcSEcCtD
Lubiprostone—Anorexia—Gemcitabine—kidney cancer	0.000292	0.000993	CcSEcCtD
Lubiprostone—Oedema peripheral—Capecitabine—kidney cancer	0.000292	0.000993	CcSEcCtD
Lubiprostone—Vomiting—Vinblastine—kidney cancer	0.000292	0.000992	CcSEcCtD
Lubiprostone—Dizziness—Erlotinib—kidney cancer	0.000292	0.000992	CcSEcCtD
Lubiprostone—Ill-defined disorder—Paclitaxel—kidney cancer	0.000292	0.000992	CcSEcCtD
Lubiprostone—Connective tissue disorder—Capecitabine—kidney cancer	0.000291	0.00099	CcSEcCtD
Lubiprostone—Vomiting—Everolimus—kidney cancer	0.000291	0.000988	CcSEcCtD
Lubiprostone—Rash—Everolimus—kidney cancer	0.000288	0.00098	CcSEcCtD
Lubiprostone—Dermatitis—Everolimus—kidney cancer	0.000288	0.000979	CcSEcCtD
Lubiprostone—Headache—Vinblastine—kidney cancer	0.000288	0.000978	CcSEcCtD
Lubiprostone—Headache—Everolimus—kidney cancer	0.000286	0.000974	CcSEcCtD
Lubiprostone—Abdominal pain—Dactinomycin—kidney cancer	0.000286	0.000972	CcSEcCtD
Lubiprostone—Asthenia—Sorafenib—kidney cancer	0.000285	0.000968	CcSEcCtD
Lubiprostone—Malaise—Paclitaxel—kidney cancer	0.000283	0.000964	CcSEcCtD
Lubiprostone—Syncope—Paclitaxel—kidney cancer	0.000282	0.000959	CcSEcCtD
Lubiprostone—Lethargy—Doxorubicin—kidney cancer	0.000282	0.000958	CcSEcCtD
Lubiprostone—Hypersensitivity—Sunitinib—kidney cancer	0.000281	0.000957	CcSEcCtD
Lubiprostone—Decreased appetite—Vincristine—kidney cancer	0.000281	0.000955	CcSEcCtD
Lubiprostone—Vomiting—Erlotinib—kidney cancer	0.00028	0.000954	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000279	0.000949	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Vincristine—kidney cancer	0.000279	0.000948	CcSEcCtD
Lubiprostone—Fatigue—Vincristine—kidney cancer	0.000278	0.000947	CcSEcCtD
Lubiprostone—Rash—Erlotinib—kidney cancer	0.000278	0.000946	CcSEcCtD
Lubiprostone—Dermatitis—Erlotinib—kidney cancer	0.000278	0.000945	CcSEcCtD
Lubiprostone—Palpitations—Paclitaxel—kidney cancer	0.000278	0.000945	CcSEcCtD
Lubiprostone—Headache—Erlotinib—kidney cancer	0.000276	0.00094	CcSEcCtD
Lubiprostone—Loss of consciousness—Paclitaxel—kidney cancer	0.000276	0.000939	CcSEcCtD
Lubiprostone—Constipation—Vincristine—kidney cancer	0.000276	0.000939	CcSEcCtD
Lubiprostone—Pain—Vincristine—kidney cancer	0.000276	0.000939	CcSEcCtD
Lubiprostone—Cough—Paclitaxel—kidney cancer	0.000274	0.000933	CcSEcCtD
Lubiprostone—Asthenia—Sunitinib—kidney cancer	0.000274	0.000932	CcSEcCtD
Lubiprostone—Dyspnoea—Gemcitabine—kidney cancer	0.000273	0.000929	CcSEcCtD
Lubiprostone—Nausea—Vinblastine—kidney cancer	0.000273	0.000927	CcSEcCtD
Lubiprostone—Nausea—Everolimus—kidney cancer	0.000272	0.000923	CcSEcCtD
Lubiprostone—Diarrhoea—Sorafenib—kidney cancer	0.000272	0.000923	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CA9—kidney cancer	0.000271	0.00356	CbGpPWpGaD
Lubiprostone—Myalgia—Paclitaxel—kidney cancer	0.000268	0.00091	CcSEcCtD
Lubiprostone—Chest pain—Paclitaxel—kidney cancer	0.000268	0.00091	CcSEcCtD
Lubiprostone—Mediastinal disorder—Capecitabine—kidney cancer	0.000267	0.000908	CcSEcCtD
Lubiprostone—Anxiety—Paclitaxel—kidney cancer	0.000267	0.000907	CcSEcCtD
Lubiprostone—Decreased appetite—Gemcitabine—kidney cancer	0.000266	0.000906	CcSEcCtD
Lubiprostone—Hypersensitivity—Dactinomycin—kidney cancer	0.000266	0.000906	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000266	0.000904	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	0.000265	0.00348	CbGpPWpGaD
Lubiprostone—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000265	0.0009	CcSEcCtD
Lubiprostone—Discomfort—Paclitaxel—kidney cancer	0.000264	0.000899	CcSEcCtD
Lubiprostone—Fatigue—Gemcitabine—kidney cancer	0.000264	0.000898	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Vincristine—kidney cancer	0.000264	0.000898	CcSEcCtD
Lubiprostone—Dizziness—Sorafenib—kidney cancer	0.000262	0.000892	CcSEcCtD
Lubiprostone—Constipation—Gemcitabine—kidney cancer	0.000262	0.000891	CcSEcCtD
Lubiprostone—Pain—Gemcitabine—kidney cancer	0.000262	0.000891	CcSEcCtD
Lubiprostone—Nausea—Erlotinib—kidney cancer	0.000262	0.000891	CcSEcCtD
Lubiprostone—Dry mouth—Paclitaxel—kidney cancer	0.000262	0.00089	CcSEcCtD
Lubiprostone—Diarrhoea—Sunitinib—kidney cancer	0.000261	0.000888	CcSEcCtD
Lubiprostone—Mental disorder—Capecitabine—kidney cancer	0.00026	0.000883	CcSEcCtD
Lubiprostone—Asthenia—Dactinomycin—kidney cancer	0.000259	0.000882	CcSEcCtD
Lubiprostone—Erythema—Capecitabine—kidney cancer	0.000258	0.000877	CcSEcCtD
Lubiprostone—Malnutrition—Capecitabine—kidney cancer	0.000258	0.000877	CcSEcCtD
Lubiprostone—Oedema—Paclitaxel—kidney cancer	0.000257	0.000872	CcSEcCtD
Lubiprostone—Abdominal pain—Vincristine—kidney cancer	0.000255	0.000868	CcSEcCtD
Lubiprostone—Flatulence—Capecitabine—kidney cancer	0.000254	0.000864	CcSEcCtD
Lubiprostone—Dysgeusia—Capecitabine—kidney cancer	0.000253	0.000859	CcSEcCtD
Lubiprostone—Dizziness—Sunitinib—kidney cancer	0.000253	0.000859	CcSEcCtD
Lubiprostone—Feeling abnormal—Gemcitabine—kidney cancer	0.000252	0.000859	CcSEcCtD
Lubiprostone—Shock—Paclitaxel—kidney cancer	0.000252	0.000858	CcSEcCtD
Lubiprostone—Vomiting—Sorafenib—kidney cancer	0.000252	0.000858	CcSEcCtD
Lubiprostone—Nervous system disorder—Paclitaxel—kidney cancer	0.000252	0.000855	CcSEcCtD
Lubiprostone—Tachycardia—Paclitaxel—kidney cancer	0.00025	0.000851	CcSEcCtD
Lubiprostone—Rash—Sorafenib—kidney cancer	0.00025	0.000851	CcSEcCtD
Lubiprostone—Dermatitis—Sorafenib—kidney cancer	0.00025	0.00085	CcSEcCtD
Lubiprostone—Skin disorder—Paclitaxel—kidney cancer	0.000249	0.000847	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000249	0.000845	CcSEcCtD
Lubiprostone—Headache—Sorafenib—kidney cancer	0.000249	0.000845	CcSEcCtD
Lubiprostone—Muscle spasms—Capecitabine—kidney cancer	0.000248	0.000843	CcSEcCtD
Lubiprostone—Hyperhidrosis—Paclitaxel—kidney cancer	0.000248	0.000843	CcSEcCtD
Lubiprostone—Diarrhoea—Dactinomycin—kidney cancer	0.000247	0.000841	CcSEcCtD
Lubiprostone—Anorexia—Paclitaxel—kidney cancer	0.000245	0.000832	CcSEcCtD
Lubiprostone—Gastritis—Doxorubicin—kidney cancer	0.000244	0.000831	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000244	0.000828	CcSEcCtD
Lubiprostone—Vomiting—Sunitinib—kidney cancer	0.000243	0.000826	CcSEcCtD
Lubiprostone—Tremor—Capecitabine—kidney cancer	0.000242	0.000822	CcSEcCtD
Lubiprostone—Rash—Sunitinib—kidney cancer	0.000241	0.000819	CcSEcCtD
Lubiprostone—Dermatitis—Sunitinib—kidney cancer	0.000241	0.000818	CcSEcCtD
Lubiprostone—Abdominal distension—Doxorubicin—kidney cancer	0.00024	0.000817	CcSEcCtD
Lubiprostone—Ill-defined disorder—Capecitabine—kidney cancer	0.000239	0.000814	CcSEcCtD
Lubiprostone—Headache—Sunitinib—kidney cancer	0.000239	0.000813	CcSEcCtD
Lubiprostone—Influenza—Doxorubicin—kidney cancer	0.000239	0.000811	CcSEcCtD
Lubiprostone—Hypersensitivity—Vincristine—kidney cancer	0.000238	0.000809	CcSEcCtD
Lubiprostone—Nausea—Sorafenib—kidney cancer	0.000236	0.000802	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000234	0.000795	CcSEcCtD
Lubiprostone—Malaise—Capecitabine—kidney cancer	0.000233	0.000791	CcSEcCtD
Lubiprostone—Asthenia—Vincristine—kidney cancer	0.000232	0.000788	CcSEcCtD
Lubiprostone—Syncope—Capecitabine—kidney cancer	0.000231	0.000787	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CRABP1—kidney cancer	0.00023	0.00303	CbGpPWpGaD
Lubiprostone—Vomiting—Dactinomycin—kidney cancer	0.00023	0.000782	CcSEcCtD
Lubiprostone—Dyspnoea—Paclitaxel—kidney cancer	0.000229	0.000778	CcSEcCtD
Lubiprostone—Palpitations—Capecitabine—kidney cancer	0.000228	0.000775	CcSEcCtD
Lubiprostone—Rash—Dactinomycin—kidney cancer	0.000228	0.000775	CcSEcCtD
Lubiprostone—Nausea—Sunitinib—kidney cancer	0.000227	0.000771	CcSEcCtD
Lubiprostone—Loss of consciousness—Capecitabine—kidney cancer	0.000227	0.000771	CcSEcCtD
Lubiprostone—Dyspepsia—Paclitaxel—kidney cancer	0.000226	0.000768	CcSEcCtD
Lubiprostone—Cough—Capecitabine—kidney cancer	0.000225	0.000765	CcSEcCtD
Lubiprostone—Decreased appetite—Paclitaxel—kidney cancer	0.000223	0.000758	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000221	0.000753	CcSEcCtD
Lubiprostone—Fatigue—Paclitaxel—kidney cancer	0.000221	0.000752	CcSEcCtD
Lubiprostone—Diarrhoea—Vincristine—kidney cancer	0.000221	0.000751	CcSEcCtD
Lubiprostone—Pollakiuria—Doxorubicin—kidney cancer	0.00022	0.00075	CcSEcCtD
Lubiprostone—Asthenia—Gemcitabine—kidney cancer	0.00022	0.000748	CcSEcCtD
Lubiprostone—Chest pain—Capecitabine—kidney cancer	0.00022	0.000747	CcSEcCtD
Lubiprostone—Myalgia—Capecitabine—kidney cancer	0.00022	0.000747	CcSEcCtD
Lubiprostone—Pain—Paclitaxel—kidney cancer	0.000219	0.000746	CcSEcCtD
Lubiprostone—Constipation—Paclitaxel—kidney cancer	0.000219	0.000746	CcSEcCtD
Lubiprostone—Anxiety—Capecitabine—kidney cancer	0.000219	0.000744	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000218	0.000742	CcSEcCtD
Lubiprostone—Weight increased—Doxorubicin—kidney cancer	0.000217	0.000738	CcSEcCtD
Lubiprostone—Discomfort—Capecitabine—kidney cancer	0.000217	0.000738	CcSEcCtD
Lubiprostone—Dry mouth—Capecitabine—kidney cancer	0.000215	0.00073	CcSEcCtD
Lubiprostone—Nausea—Dactinomycin—kidney cancer	0.000215	0.00073	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ITPR2—kidney cancer	0.000214	0.00282	CbGpPWpGaD
Lubiprostone—Dizziness—Vincristine—kidney cancer	0.000214	0.000726	CcSEcCtD
Lubiprostone—Feeling abnormal—Paclitaxel—kidney cancer	0.000211	0.000719	CcSEcCtD
Lubiprostone—Oedema—Capecitabine—kidney cancer	0.000211	0.000716	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Paclitaxel—kidney cancer	0.00021	0.000713	CcSEcCtD
Lubiprostone—Diarrhoea—Gemcitabine—kidney cancer	0.00021	0.000713	CcSEcCtD
Lubiprostone—Shock—Capecitabine—kidney cancer	0.000207	0.000704	CcSEcCtD
Lubiprostone—Urinary tract infection—Doxorubicin—kidney cancer	0.000207	0.000703	CcSEcCtD
Lubiprostone—Nervous system disorder—Capecitabine—kidney cancer	0.000206	0.000702	CcSEcCtD
Lubiprostone—Tachycardia—Capecitabine—kidney cancer	0.000205	0.000699	CcSEcCtD
Lubiprostone—Vomiting—Vincristine—kidney cancer	0.000205	0.000698	CcSEcCtD
Lubiprostone—Skin disorder—Capecitabine—kidney cancer	0.000204	0.000695	CcSEcCtD
Lubiprostone—Rash—Vincristine—kidney cancer	0.000204	0.000692	CcSEcCtD
Lubiprostone—Hyperhidrosis—Capecitabine—kidney cancer	0.000204	0.000692	CcSEcCtD
Lubiprostone—Dermatitis—Vincristine—kidney cancer	0.000203	0.000692	CcSEcCtD
Lubiprostone—Abdominal pain—Paclitaxel—kidney cancer	0.000203	0.00069	CcSEcCtD
Lubiprostone—Headache—Vincristine—kidney cancer	0.000202	0.000688	CcSEcCtD
Lubiprostone—Anorexia—Capecitabine—kidney cancer	0.000201	0.000682	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	0.000197	0.0026	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTT1—kidney cancer	0.000195	0.00257	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ACHE—kidney cancer	0.000195	0.00257	CbGpPWpGaD
Lubiprostone—Vomiting—Gemcitabine—kidney cancer	0.000195	0.000662	CcSEcCtD
Lubiprostone—Rash—Gemcitabine—kidney cancer	0.000193	0.000657	CcSEcCtD
Lubiprostone—Dermatitis—Gemcitabine—kidney cancer	0.000193	0.000656	CcSEcCtD
Lubiprostone—Headache—Gemcitabine—kidney cancer	0.000192	0.000653	CcSEcCtD
Lubiprostone—Nausea—Vincristine—kidney cancer	0.000192	0.000652	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000192	0.000652	CcSEcCtD
Lubiprostone—Hypersensitivity—Paclitaxel—kidney cancer	0.000189	0.000643	CcSEcCtD
Lubiprostone—Oedema peripheral—Doxorubicin—kidney cancer	0.000188	0.00064	CcSEcCtD
Lubiprostone—Connective tissue disorder—Doxorubicin—kidney cancer	0.000188	0.000638	CcSEcCtD
Lubiprostone—Dyspnoea—Capecitabine—kidney cancer	0.000188	0.000638	CcSEcCtD
Lubiprostone—Dyspepsia—Capecitabine—kidney cancer	0.000185	0.00063	CcSEcCtD
Lubiprostone—CBR1—Metabolism—SCARB1—kidney cancer	0.000185	0.00243	CbGpPWpGaD
Lubiprostone—Asthenia—Paclitaxel—kidney cancer	0.000184	0.000626	CcSEcCtD
Lubiprostone—Decreased appetite—Capecitabine—kidney cancer	0.000183	0.000622	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PTGS1—kidney cancer	0.000183	0.00241	CbGpPWpGaD
Lubiprostone—Nausea—Gemcitabine—kidney cancer	0.000182	0.000619	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000182	0.000618	CcSEcCtD
Lubiprostone—Fatigue—Capecitabine—kidney cancer	0.000182	0.000617	CcSEcCtD
Lubiprostone—Pain—Capecitabine—kidney cancer	0.00018	0.000612	CcSEcCtD
Lubiprostone—Constipation—Capecitabine—kidney cancer	0.00018	0.000612	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PSMD7—kidney cancer	0.000179	0.00236	CbGpPWpGaD
Lubiprostone—Diarrhoea—Paclitaxel—kidney cancer	0.000176	0.000597	CcSEcCtD
Lubiprostone—Feeling abnormal—Capecitabine—kidney cancer	0.000173	0.00059	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Capecitabine—kidney cancer	0.000172	0.000585	CcSEcCtD
Lubiprostone—Mediastinal disorder—Doxorubicin—kidney cancer	0.000172	0.000585	CcSEcCtD
Lubiprostone—CBR1—Metabolism—BCHE—kidney cancer	0.00017	0.00224	CbGpPWpGaD
Lubiprostone—Dizziness—Paclitaxel—kidney cancer	0.00017	0.000577	CcSEcCtD
Lubiprostone—CBR1—Metabolism—SLC5A5—kidney cancer	0.000168	0.00221	CbGpPWpGaD
Lubiprostone—Mental disorder—Doxorubicin—kidney cancer	0.000167	0.000569	CcSEcCtD
Lubiprostone—Abdominal pain—Capecitabine—kidney cancer	0.000166	0.000566	CcSEcCtD
Lubiprostone—Malnutrition—Doxorubicin—kidney cancer	0.000166	0.000565	CcSEcCtD
Lubiprostone—Erythema—Doxorubicin—kidney cancer	0.000166	0.000565	CcSEcCtD
Lubiprostone—Flatulence—Doxorubicin—kidney cancer	0.000164	0.000557	CcSEcCtD
Lubiprostone—Vomiting—Paclitaxel—kidney cancer	0.000163	0.000555	CcSEcCtD
Lubiprostone—Dysgeusia—Doxorubicin—kidney cancer	0.000163	0.000554	CcSEcCtD
Lubiprostone—CBR1—Metabolism—SLC2A1—kidney cancer	0.000162	0.00213	CbGpPWpGaD
Lubiprostone—Rash—Paclitaxel—kidney cancer	0.000162	0.00055	CcSEcCtD
Lubiprostone—Dermatitis—Paclitaxel—kidney cancer	0.000162	0.00055	CcSEcCtD
Lubiprostone—Headache—Paclitaxel—kidney cancer	0.000161	0.000546	CcSEcCtD
Lubiprostone—Muscle spasms—Doxorubicin—kidney cancer	0.00016	0.000544	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	0.000157	0.00207	CbGpPWpGaD
Lubiprostone—Hypersensitivity—Capecitabine—kidney cancer	0.000155	0.000527	CcSEcCtD
Lubiprostone—Ill-defined disorder—Doxorubicin—kidney cancer	0.000154	0.000525	CcSEcCtD
Lubiprostone—Nausea—Paclitaxel—kidney cancer	0.000152	0.000518	CcSEcCtD
Lubiprostone—Asthenia—Capecitabine—kidney cancer	0.000151	0.000514	CcSEcCtD
Lubiprostone—Malaise—Doxorubicin—kidney cancer	0.00015	0.00051	CcSEcCtD
Lubiprostone—Syncope—Doxorubicin—kidney cancer	0.000149	0.000507	CcSEcCtD
Lubiprostone—Palpitations—Doxorubicin—kidney cancer	0.000147	0.0005	CcSEcCtD
Lubiprostone—Loss of consciousness—Doxorubicin—kidney cancer	0.000146	0.000497	CcSEcCtD
Lubiprostone—Cough—Doxorubicin—kidney cancer	0.000145	0.000493	CcSEcCtD
Lubiprostone—Diarrhoea—Capecitabine—kidney cancer	0.000144	0.00049	CcSEcCtD
Lubiprostone—Myalgia—Doxorubicin—kidney cancer	0.000142	0.000481	CcSEcCtD
Lubiprostone—Chest pain—Doxorubicin—kidney cancer	0.000142	0.000481	CcSEcCtD
Lubiprostone—Anxiety—Doxorubicin—kidney cancer	0.000141	0.00048	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000141	0.000478	CcSEcCtD
Lubiprostone—Discomfort—Doxorubicin—kidney cancer	0.00014	0.000476	CcSEcCtD
Lubiprostone—Dizziness—Capecitabine—kidney cancer	0.000139	0.000473	CcSEcCtD
Lubiprostone—Dry mouth—Doxorubicin—kidney cancer	0.000138	0.000471	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	0.000137	0.00181	CbGpPWpGaD
Lubiprostone—Oedema—Doxorubicin—kidney cancer	0.000136	0.000461	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTP1—kidney cancer	0.000135	0.00178	CbGpPWpGaD
Lubiprostone—Vomiting—Capecitabine—kidney cancer	0.000134	0.000455	CcSEcCtD
Lubiprostone—Shock—Doxorubicin—kidney cancer	0.000134	0.000454	CcSEcCtD
Lubiprostone—Nervous system disorder—Doxorubicin—kidney cancer	0.000133	0.000453	CcSEcCtD
Lubiprostone—Rash—Capecitabine—kidney cancer	0.000133	0.000451	CcSEcCtD
Lubiprostone—Dermatitis—Capecitabine—kidney cancer	0.000133	0.000451	CcSEcCtD
Lubiprostone—Tachycardia—Doxorubicin—kidney cancer	0.000132	0.00045	CcSEcCtD
Lubiprostone—Headache—Capecitabine—kidney cancer	0.000132	0.000448	CcSEcCtD
Lubiprostone—Skin disorder—Doxorubicin—kidney cancer	0.000132	0.000448	CcSEcCtD
Lubiprostone—Hyperhidrosis—Doxorubicin—kidney cancer	0.000131	0.000446	CcSEcCtD
Lubiprostone—Anorexia—Doxorubicin—kidney cancer	0.000129	0.00044	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ABCB1—kidney cancer	0.000128	0.00168	CbGpPWpGaD
Lubiprostone—Nausea—Capecitabine—kidney cancer	0.000125	0.000425	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTM1—kidney cancer	0.000124	0.00164	CbGpPWpGaD
Lubiprostone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000124	0.00042	CcSEcCtD
Lubiprostone—Dyspnoea—Doxorubicin—kidney cancer	0.000121	0.000411	CcSEcCtD
Lubiprostone—Dyspepsia—Doxorubicin—kidney cancer	0.000119	0.000406	CcSEcCtD
Lubiprostone—Decreased appetite—Doxorubicin—kidney cancer	0.000118	0.000401	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CYP1A1—kidney cancer	0.000118	0.00155	CbGpPWpGaD
Lubiprostone—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000117	0.000398	CcSEcCtD
Lubiprostone—Fatigue—Doxorubicin—kidney cancer	0.000117	0.000398	CcSEcCtD
Lubiprostone—Pain—Doxorubicin—kidney cancer	0.000116	0.000395	CcSEcCtD
Lubiprostone—Constipation—Doxorubicin—kidney cancer	0.000116	0.000395	CcSEcCtD
Lubiprostone—Feeling abnormal—Doxorubicin—kidney cancer	0.000112	0.00038	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000111	0.000377	CcSEcCtD
Lubiprostone—Abdominal pain—Doxorubicin—kidney cancer	0.000107	0.000365	CcSEcCtD
Lubiprostone—Hypersensitivity—Doxorubicin—kidney cancer	0.0001	0.00034	CcSEcCtD
Lubiprostone—Asthenia—Doxorubicin—kidney cancer	9.74e-05	0.000331	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.69e-05	0.00127	CbGpPWpGaD
Lubiprostone—Diarrhoea—Doxorubicin—kidney cancer	9.28e-05	0.000316	CcSEcCtD
Lubiprostone—Dizziness—Doxorubicin—kidney cancer	8.97e-05	0.000305	CcSEcCtD
Lubiprostone—CBR1—Metabolism—POMC—kidney cancer	8.79e-05	0.00116	CbGpPWpGaD
Lubiprostone—Vomiting—Doxorubicin—kidney cancer	8.63e-05	0.000293	CcSEcCtD
Lubiprostone—Rash—Doxorubicin—kidney cancer	8.56e-05	0.000291	CcSEcCtD
Lubiprostone—Dermatitis—Doxorubicin—kidney cancer	8.55e-05	0.000291	CcSEcCtD
Lubiprostone—Headache—Doxorubicin—kidney cancer	8.5e-05	0.000289	CcSEcCtD
Lubiprostone—Nausea—Doxorubicin—kidney cancer	8.06e-05	0.000274	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PTGS2—kidney cancer	7.01e-05	0.000922	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTEN—kidney cancer	6.11e-05	0.000804	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CA—kidney cancer	4.31e-05	0.000567	CbGpPWpGaD
